Periodic Reporting for period 1 - IMPACT- AML (Master Framework and Pragmatic Clinical Trial for Relapse or Refractory Acute Myeloid Leukemia)

Acute Myeloid Leukemia (AML) is an aggressive blood cancer with a poor prognosis, especially for patients with relapse or treatment resistance (R/R AML). Current treatment options are limited, highlighting the urgent need for better therapies and broader access to quality...